Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics


Supernus Pharmaceuticals, Inc. (SUPN)

Today's Latest Price: $19.87 USD

0.22 (-1.10%)

Updated Oct 26 9:38am

Add SUPN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SUPN Stock Summary

  • With a price/earnings ratio of 8.8, Supernus Pharmaceuticals Inc P/E ratio is greater than that of about just 15.04% of stocks in our set with positive earnings.
  • Over the past twelve months, SUPN has reported earnings growth of 24.62%, putting it ahead of 75.27% of US stocks in our set.
  • The volatility of Supernus Pharmaceuticals Inc's share price is greater than that of only 16.73% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Supernus Pharmaceuticals Inc are VIAV, LMNX, NOVT, ACIW, and DGII.
  • SUPN's SEC filings can be seen here. And to visit Supernus Pharmaceuticals Inc's official web site, go to www.supernus.com.

SUPN Stock Price Chart Interactive Chart >

Price chart for SUPN

SUPN Price/Volume Stats

Current price $19.87 52-week high $29.36
Prev. close $20.09 52-week low $13.12
Day low $19.85 Volume 4,159
Day high $20.06 Avg. volume 522,169
50-day MA $21.39 Dividend yield N/A
200-day MA $21.76 Market Cap 1.05B

Supernus Pharmaceuticals, Inc. (SUPN) Company Bio


Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.

SUPN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$19.87$567.93 2727%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Supernus Pharmaceuticals Inc. To summarize, we found that Supernus Pharmaceuticals Inc ranked in the 91th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Supernus Pharmaceuticals Inc ended up being:

  • Its compound free cash flow growth rate, as measured over the past 5.44 years, is 0.8% -- higher than 88.25% of stocks in our DCF forecasting set.
  • Supernus Pharmaceuticals Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 14.04% of tickers in our DCF set.
  • As a business, Supernus Pharmaceuticals Inc experienced a tax rate of about 17% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 73.85% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%2671%
1%2699%
2%2727%
3%2755%
4%2782%
5%2810%

Want more companies with a valuation profile/forecast similar to that of Supernus Pharmaceuticals Inc? See OMI, RDY, ANIP, AMS, and CYH.


SUPN Latest News Stream


Event/Time News Detail
Loading, please wait...

SUPN Latest Social Stream


Loading social stream, please wait...

View Full SUPN Social Stream

Latest SUPN News From Around the Web

Below are the latest news stories about Supernus Pharmaceuticals Inc that investors may wish to consider to help them evaluate SUPN as an investment opportunity.

Supernus: Launch Preparations In Progress

An issue dogging Supernus (SUPN) is potential generic competition for Trokendi XR in 2023 (p. 28). Trokendi XR has been Supernus' long-term revenue driver since 2014. It made up 73% (p. 19) of the company's net product sales for the first six months of 2020. Any challenge to its earnings...

Out of Ignorance on Seeking Alpha | September 29, 2020

Supernus' Value Proposition Has Improved With Recent Sell-Off

Supernus (SUPN) is a long-term holding of mine that I first wrote about in May shortly after the company had acquired the CNS assets of US WorldMeds and before any 2020 financial data had been released. I discussed how this type of acquisition seemed like a prudent use of free...

Andy Jones on Seeking Alpha | September 28, 2020

Will Supernus (SUPN) Beat Estimates Again in Its Next Earnings Report?

Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo | July 30, 2020

Supernus Sues Apotex for Infringement of Oxtellar XR® Patents

Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that earlier today it sued generic drug maker Apotex Inc. and Apotex Corp. (collectively, Apotex) for infringement of nine patents covering its antiepileptic drug Oxtellar XR®. The Complaint – filed in the U.S. District Court for the District of New Jersey – alleges that Apotex infringed Supernus's Oxtellar XR patents by submitting to the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) seeking to market a generic version of Oxtellar XR prior to the expiration of Supernus's patents. Filing its Complaint within 45 days of receiving Apotex’s Paragraph IV certification not...

Yahoo | June 26, 2020

Supernus Pharmaceuticals Inc (SUPN): Hedge Funds Are Snapping Up

In this article we will take a look at whether hedge funds think Supernus Pharmaceuticals Inc (NASDAQ:SUPN) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

Yahoo | June 19, 2020

Read More 'SUPN' Stories Here

SUPN Price Returns

1-mo -2.17%
3-mo -14.39%
6-mo -15.70%
1-year -27.69%
3-year -51.83%
5-year 17.50%
YTD -16.23%
2019 -28.60%
2018 -16.64%
2017 57.82%
2016 87.87%
2015 61.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8693 seconds.